Ovid Therapeutics Inc. (OVID) stock
OVIDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 10/30
$2.22−0.18 (-7.50%)
Close on Nov 17, 2026Market cap $433.56MP/E –Yield –
Ovid Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Ovid Therapeutics's enterprise value was $343.85M on Nov 11, 2026, against $101.05M a year earlier. Over the last 5 years it ranged from -$49.59M to $343.85M, with a median of $52.80M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $343.85M | +280.5% |
| 2025 | Dec 31, 2025 | $90.37M | +2417.5% |
| 2024 | Dec 31, 2024 | $3.59M | -97.4% |
| 2023 | Dec 29, 2023 | $140.52M | – |
| 2022 | Dec 30, 2022 | -$6.79M | -141.0% |
| 2021 | Dec 31, 2021 | $16.55M | -72.3% |
| 2020 | Dec 31, 2020 | $59.67M | -49.3% |
| 2019 | Dec 31, 2019 | $117.58M | +1543.2% |
| 2018 | Dec 31, 2018 | $7.16M | -95.1% |
| 2017 | Dec 29, 2017 | $146.78M | – |
See a number that looks wrong?